Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H28N4O3 |
| Molecular Weight | 384.472 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C1CCCCC1)C(=O)CCCOC2=CC3=C(NC4=NC(=O)CN4C3)C=C2
InChI
InChIKey=WUECXCBONAGRSA-UHFFFAOYSA-N
InChI=1S/C21H28N4O3/c1-24(16-6-3-2-4-7-16)20(27)8-5-11-28-17-9-10-18-15(12-17)13-25-14-19(26)23-21(25)22-18/h9-10,12,16H,2-8,11,13-14H2,1H3,(H,22,23,26)
Lixazinone selectively inhibits the high-affinity form of cyclic AMP phosphodiesterase (type IV) isolated from human platelets with only weak effects on both the nonspecific and cyclic GMP-sensitive phosphodiesterases. The inhibitor reduces both maximum velocity and substrate affinity of the type IV enzyme. Lixazinone exhibits marked selectively for the platelet high-affinity enzyme. It also has significant inhibitory effects on cardiac membrane-bound phosphodiesterase. Lixazinone may be useful as an agent to increase cardiac output in the treatment of congestive heart failure. It is a potent PDE3 inhibitor. Lixazinone suppresses folic acid-induced proliferation of rat tubular epithelial cells in vivo.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties. | 1986 Jun |
|
| RS-82856, a selective phosphodiesterase inhibitor with inotropic, afterload reduction and antithrombotic properties. | 1987 |
|
| Electrochemical evaluation of the interaction between ascorbic acid and the cardiotonic drug RS-82856. | 1987 Dec |
|
| Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide (RS-82856). | 1987 Feb |
|
| Parenteral formulation development for the positive inotropic agent RS-82856: solubility and stability enhancement through complexation and lyophilization. | 1987 Jul-Aug |
|
| Inhibitors of cyclic AMP phosphodiesterase. 4. Synthesis and evaluation of potential prodrugs of lixazinone (N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro-2- oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide, RS-82856). | 1988 Nov |
|
| Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazoline. | 1988 Nov |
|
| Analysis of the binding sites for the cardiotonic phosphodiesterase inhibitor [3H]LY186126 in ventricular myocardium. | 1989 Aug |
|
| Photoaffinity labelling of cyclic GMP-inhibited phosphodiesterase (PDE III) in human and rat platelets and rat tissues: effects of phosphodiesterase inhibitors. | 1994 Jun 15 |
|
| Inhibitors of cyclic nucleotide phosphodiesterase isozymes type-III and type-IV suppress mitogenesis of rat mesangial cells. | 1995 Jul |
|
| Suppression of mesangial proliferative glomerulonephritis development in rats by inhibitors of cAMP phosphodiesterase isozymes types III and IV. | 1996 Jul 15 |
|
| Expression and mutagenesis of the catalytic domain of cGMP-inhibited phosphodiesterase (PDE3) cloned from human platelets. | 1997 Apr 1 |
|
| Compartmentalization of cAMP signaling in mesangial cells by phosphodiesterase isozymes PDE3 and PDE4. Regulation of superoxidation and mitogenesis. | 1997 Apr 11 |
|
| Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation. | 1997 Apr 15 |
|
| Inhibitors of cyclic nucleotide phosphodiesterase isozymes block renal tubular cell proliferation induced by folic acid. | 1997 Nov |
|
| Signaling role of PDE isozymes in pathobiology of glomerular mesangial cells. Studies in vitro and in vivo. | 1998 |
|
| Functions of the N-terminal region of cyclic nucleotide phosphodiesterase 3 (PDE 3) isoforms. | 2000 Apr 21 |
|
| Lixazinone stimulates mitogenesis of Madin-Darby canine kidney cells. | 2006 Mar |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6141
Created by
admin on Fri Dec 15 18:48:50 GMT 2023 , Edited by admin on Fri Dec 15 18:48:50 GMT 2023
|
PRIMARY | |||
|
C049443
Created by
admin on Fri Dec 15 18:48:50 GMT 2023 , Edited by admin on Fri Dec 15 18:48:50 GMT 2023
|
PRIMARY | |||
|
CHEMBL69139
Created by
admin on Fri Dec 15 18:48:50 GMT 2023 , Edited by admin on Fri Dec 15 18:48:50 GMT 2023
|
PRIMARY | |||
|
SUB08539MIG
Created by
admin on Fri Dec 15 18:48:50 GMT 2023 , Edited by admin on Fri Dec 15 18:48:50 GMT 2023
|
PRIMARY | |||
|
135434015
Created by
admin on Fri Dec 15 18:48:50 GMT 2023 , Edited by admin on Fri Dec 15 18:48:50 GMT 2023
|
PRIMARY | |||
|
100000082527
Created by
admin on Fri Dec 15 18:48:50 GMT 2023 , Edited by admin on Fri Dec 15 18:48:50 GMT 2023
|
PRIMARY | |||
|
C175114
Created by
admin on Fri Dec 15 18:48:50 GMT 2023 , Edited by admin on Fri Dec 15 18:48:50 GMT 2023
|
PRIMARY | |||
|
DTXSID70240931
Created by
admin on Fri Dec 15 18:48:50 GMT 2023 , Edited by admin on Fri Dec 15 18:48:50 GMT 2023
|
PRIMARY | |||
|
0FK7P66P1X
Created by
admin on Fri Dec 15 18:48:50 GMT 2023 , Edited by admin on Fri Dec 15 18:48:50 GMT 2023
|
PRIMARY | |||
|
94192-59-3
Created by
admin on Fri Dec 15 18:48:50 GMT 2023 , Edited by admin on Fri Dec 15 18:48:50 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
